LOS ANGELES, CA, Jan. 11, 2018 (GLOBE NEWSWIRE) — Endonovo Therapeutics, Inc. (OTCQB: ENDV) (“Endonovo” or the “Company”), a clinical-stage developer of non-invasive electroceuticals for the treatment of central nervous system (CNS) disorders, today announced it is working with ShareIntel – Shareholder Intelligence Services to continue its commitment to protecting its shareholders and maximizing shareholder value. ShareIntel offers unprecedented access and insight into broker-dealer, clearing firm and shareholder position movement. ShareIntel utilizes a patented process called DRIL-DownTM to aggregate and analyze historic repository dataRead more
- Research on Lodonal for HIV related GI complications featured in Plus Magazine
- Cannabis Strategic Ventures and Sunniva Inc. Enter Into Cannabis Extraction Services Agreement
- Precision Therapeutics Merger with Helomics Corp. Accelerates Personalized Cancer Treatment Strategies
- Precision Therapeutics Granted European Patent for its Automated, Direct-to-Drain Medical Fluid Disposal System
- PHI Group Partners with Fintech Green Investment Company
SMALL CAP MARKET NEWS
We release small market news updates daily, 5 times a week! Always check back to get the inside scoop on what going on.
LEVERAGE OUR MASSIVE INVESTOR AUDIENCE!
Stock Investors · Accredited Investors · Hedge Fund InvestorsLearn More